Your browser doesn't support javascript.
loading
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith, Jennifer; Bansi-Matharu, Loveleen; Cambiano, Valentina; Dimitrov, Dobromir; Bershteyn, Anna; van de Vijver, David; Kripke, Katharine; Revill, Paul; Boily, Marie-Claude; Meyer-Rath, Gesine; Taramusi, Isaac; Lundgren, Jens D; van Oosterhout, Joep J; Kuritzkes, Daniel; Schaefer, Robin; Siedner, Mark J; Schapiro, Jonathan; Delany-Moretlwe, Sinead; Landovitz, Raphael J; Flexner, Charles; Jordan, Michael; Venter, Francois; Radebe, Mopo; Ripin, David; Jenkins, Sarah; Resar, Danielle; Amole, Carolyn; Shahmanesh, Maryam; Gupta, Ravindra K; Raizes, Elliot; Johnson, Cheryl; Inzaule, Seth; Shafer, Robert; Warren, Mitchell; Stansfield, Sarah; Paredes, Roger; Phillips, Andrew N.
Afiliación
  • Smith J; Institute for Global Health, University College London, London, UK.
  • Bansi-Matharu L; Institute for Global Health, University College London, London, UK.
  • Cambiano V; Institute for Global Health, University College London, London, UK.
  • Dimitrov D; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Bershteyn A; Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.
  • van de Vijver D; Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Kripke K; Avenir Health, Takoma Park, MD, USA.
  • Revill P; Centre for Health Economics, University of York, York, UK.
  • Boily MC; MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
  • Meyer-Rath G; Health Economics and Epidemiology Research Office (HE2RO), Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Taramusi I; National AIDS Council, Harare, Zimbabwe.
  • Lundgren JD; Department of Clinical Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • van Oosterhout JJ; Partners in Hope, Lilongwe, Malawi; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Kuritzkes D; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Schaefer R; Global HIV, Hepatitis, and STIs Programmes, WHO, Geneva, Switzerland.
  • Siedner MJ; Department of Medicine, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Clinical Research Department, Africa Health Research Institute, Mtubatuba, South Africa.
  • Schapiro J; National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel.
  • Delany-Moretlwe S; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Landovitz RJ; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Center for Clinical AIDS Research and Education, University of California, Los Angeles, CA, USA.
  • Flexner C; Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
  • Jordan M; Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
  • Venter F; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Radebe M; Regional Office for Africa, WHO, Gauteng, South Africa.
  • Ripin D; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA.
  • Jenkins S; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA.
  • Resar D; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA.
  • Amole C; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA.
  • Shahmanesh M; Institute for Global Health, University College London, London, UK; Clinical Research Department, Africa Health Research Institute, Mtubatuba, South Africa.
  • Gupta RK; Clinical Research Department, Africa Health Research Institute, Mtubatuba, South Africa; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Raizes E; US Department of Health and Human Services, Centers for Disease Control, Atlanta, GA, USA.
  • Johnson C; Global HIV, Hepatitis, and STIs Programmes, WHO, Geneva, Switzerland.
  • Inzaule S; Global HIV, Hepatitis, and STIs Programmes, WHO, Geneva, Switzerland.
  • Shafer R; Department of Medicine, Stanford University, Palo Alto, CA, USA.
  • Warren M; AVAC, New York, NY, USA.
  • Stansfield S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Paredes R; Department of Infectious Diseases, Irsi Caixa Institut de Recerca de la SIDA, Barcelona, Spain.
  • Phillips AN; Institute for Global Health, University College London, London, UK. Electronic address: andrew.phillips@ucl.ac.uk.
Lancet HIV ; 10(4): e254-e265, 2023 04.
Article en En | MEDLINE | ID: mdl-36642087
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Síndrome de Inmunodeficiencia Adquirida / Inhibidores de Integrasa VIH / Fármacos Anti-VIH / Profilaxis Pre-Exposición Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lancet HIV Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Síndrome de Inmunodeficiencia Adquirida / Inhibidores de Integrasa VIH / Fármacos Anti-VIH / Profilaxis Pre-Exposición Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lancet HIV Año: 2023 Tipo del documento: Article